Tat’yana Aleksandrovna Sidorova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tat’yana Aleksandrovna Sidorova has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
D. A. Khochenkov
NN Blokhin National Medical Cancer Research Center, 24 Kashirskoye sh., Moscow, Russian Federation, 115478
2 shared publications- Dmitrii A. Khochenkov
Institute of Experimental Diagnostics and Treatment of Cancer N.N. Blokhin Cancer Research Center Moscow Russia
2 shared publications O. O. Ryabaya
NN Blokhin National Medical Cancer Research Center, 24 Kashirskoye sh., Moscow, Russian Federation, 115478
2 shared publicationsA. A. Prokof’eva
NN Blokhin National Medical Cancer Research Center, 24 Kashirskoye sh., Moscow, Russian Federation, 115478
1 shared publicationA. A. Prokof’yEva
N.N. Blokhin NMRCO Ministry of Health of Russia
1 shared publication- Anastasia Prokofieva
Huntsman Cancer Institute, University of Utah Health Sciences Center , Salt Lake City, UT
1 shared publication
Latest Publications
- Open Access
- 12 October 2020
- Published by Publishing House ABV Press in Russian Journal of Biotherapy
- Vol. 19 (3) , 38-45
THE VALUE OF BASAL EXPRESSION LEVEL OF HEMOXYGENASE-1 FOR SENSITIVITY OF HUMAN MELANOMA CELLS TO OXIDATIVE STRESS IN VITRO
Introduction. The molecular basis of radio- and photodynamic therapy (PDT), the mechanism of action of a number of antitumor chemotherapy drugs is oxidative stress (OS). The enzyme hemoxygenase-I (НO-1), a molecular marker of OS, is a key participant in the system of protection and adaptation of tumor cells under stress.Objective. To find out whether the sensitivity of human melanoma tumor cells to OS depends on the basal and modulator-induced levels of НO-1 expressionMaterial and methods. Human melanoma cell lines were used in the study. The expression of mRNA НO-1 in cells was studied by real-time RT-PCR, the reactive oxygen species content in cells – by flow cytometry and the cytotoxicity of drugs – by MTT assay.Results. According to our data, human melanoma cells have different basal levels of HO-1 transcription: high (3.0–3.5 o. u.) in lines MelIL, MelP, medium (1.5 o. u.) in lines MeWo, MelZ, MelIbr and low (0.5 o. e.) – MelMe, A375).There is no direct correlation between the level of basal cell expression of HO-1 and their sensitivity to the OS inducer – Н2О2. The hemin-induced increase in HO-1 expression in cells is accompanied by doubled resistance to Н2О2. It was found that HO-1 repression in the presence of apigenin was registered in melanoma cells with different basal levels, but sensitization to Н2О2 (2–4 times) was observed only for cells with medium (MeWo) and low (A375) levels of basal HO-1 expression. It was found that the decrease in basal expression of HO-1 induced by apigenin is accompanied by an increase in the reactive oxygen species content in cells.Conclusions. The results of our research allow us to recommend natural flavon apigenin, a modulator of HO-1 expression, for inclusion in the chemotherapy and PDT regimens to increase the effectiveness of human melanoma treatment.
- 12 October 2020
- Published by Publishing House ABV Press in Russian Journal of Biotherapy
- Vol. 19 (3) , 38-45
Open AccessTHE VALUE OF BASAL EXPRESSION LEVEL OF HEMOXYGENASE-1 FOR SENSITIVITY OF HUMAN MELANOMA CELLS TO OXIDATIVE STRESS IN VITRO
Introduction. The molecular basis of radio- and photodynamic therapy (PDT), the mechanism of action of a number of antitumor chemotherapy drugs is oxidative stress (OS). The enzyme hemoxygenase-I (НO-1), a molecular marker of OS, is a key participant in the system of protection and adaptation of tumor cells under stress.Objective. To find out whether the sensitivity of human melanoma tumor cells to OS depends on the basal and modulator-induced levels of НO-1 expressionMaterial and methods. Human melanoma cell lines were used in the study. The expression of mRNA НO-1 in cells was studied by real-time RT-PCR, the reactive oxygen species content in cells – by flow cytometry and the cytotoxicity of drugs – by MTT assay.Results. According to our data, human melanoma cells have different basal levels of HO-1 transcription: high (3.0–3.5 o. u.) in lines MelIL, MelP, medium (1.5 o. u.) in lines MeWo, MelZ, MelIbr and low (0.5 o. e.) – MelMe, A375).There is no direct correlation between the level of basal cell expression of HO-1 and their sensitivity to the OS inducer – Н2О2. The hemin-induced increase in HO-1 expression in cells is accompanied by doubled resistance to Н2О2. It was found that HO-1 repression in the presence of apigenin was registered in melanoma cells with different basal levels, but sensitization to Н2О2 (2–4 times) was observed only for cells with medium (MeWo) and low (A375) levels of basal HO-1 expression. It was found that the decrease in basal expression of HO-1 induced by apigenin is accompanied by an increase in the reactive oxygen species content in cells.Conclusions. The results of our research allow us to recommend natural flavon apigenin, a modulator of HO-1 expression, for inclusion in the chemotherapy and PDT regimens to increase the effectiveness of human melanoma treatment.
- Open Access
- 1 October 2019
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 12 (4)
Heme Oxygenase-1/Ferritin in Protection of Leukemia Cells from Oxidative Stress Induced by Catalytic System “Teraphtal + Ascorbic Acid”
Background. As is well known, cytotoxic mechanism of antitumor agent, i.e. catalytic system “teraphtal + ascorbic acid” (“TF+AA”), is associated with production of reactive oxygen species (ROS) and induction of oxidative stress in it. The “heme oxygenase-1/ferritin” (HО-1/Ft) system contributes to antioxidant defense. Aim. To analyze HО-1/Ft value in protection of leukemia cells from toxicity induced by antitumor agent “TF+AA”. Materials & Methods. The study was based on human leukemia cell lines K562 and U937. HО-1/Ft basal and drug-induced expression on mRNA and protein levels was analyzed by real-time RT-PCR and Western blot, ROS concentration in cells was determined by flow cytometry, and drug cytotoxicity was measured by MTT assay. Results. Our data showed constitutively active HO-1 in U937 myelomonoblasts whereas in K562 erythroblasts the expression of this protein was blocked on the mRNA level. Hemin, HO-1 agonist, induces HO-1 and Ft co-expression in U937 cells on the mRNA and protein levels. HO-1/Ft activation by hemin in U937 cells does not affect their “TF+AA” sensitivity and doubles, for example, the cytarabine sensitivity. “TF+AA” appeared to cause up-regulation of HO-1/Ft genes, the expression of which quadruples or increases by half, respectively, compared with basal level. Preincubation of U937 myelomonoblasts with deferoxamine, iron chelator, results in doubling of their “TF+AA” resistance. However, the use of iron-containing TF analogs leads to its doubled cytotoxicity. Conclusion. In leukemia cell line U937 with constitutively active НО-1/Ft the heme-dependent activation of it does not considerably contribute to protection of cells from “TF+AA” toxicity. The system “TF+AA” is HО-1 and Ft expression inducer in U937 myelomonoblasts. Cytotoxic mechanism of “TF+AA” involves intracellular pool of “labile” non-heme iron, the level of which affects the drug sensibility of leukemia cells.
- 1 October 2019
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 12 (4)
Open AccessHeme Oxygenase-1/Ferritin in Protection of Leukemia Cells from Oxidative Stress Induced by Catalytic System “Teraphtal + Ascorbic Acid”
Background. As is well known, cytotoxic mechanism of antitumor agent, i.e. catalytic system “teraphtal + ascorbic acid” (“TF+AA”), is associated with production of reactive oxygen species (ROS) and induction of oxidative stress in it. The “heme oxygenase-1/ferritin” (HО-1/Ft) system contributes to antioxidant defense. Aim. To analyze HО-1/Ft value in protection of leukemia cells from toxicity induced by antitumor agent “TF+AA”. Materials & Methods. The study was based on human leukemia cell lines K562 and U937. HО-1/Ft basal and drug-induced expression on mRNA and protein levels was analyzed by real-time RT-PCR and Western blot, ROS concentration in cells was determined by flow cytometry, and drug cytotoxicity was measured by MTT assay. Results. Our data showed constitutively active HO-1 in U937 myelomonoblasts whereas in K562 erythroblasts the expression of this protein was blocked on the mRNA level. Hemin, HO-1 agonist, induces HO-1 and Ft co-expression in U937 cells on the mRNA and protein levels. HO-1/Ft activation by hemin in U937 cells does not affect their “TF+AA” sensitivity and doubles, for example, the cytarabine sensitivity. “TF+AA” appeared to cause up-regulation of HO-1/Ft genes, the expression of which quadruples or increases by half, respectively, compared with basal level. Preincubation of U937 myelomonoblasts with deferoxamine, iron chelator, results in doubling of their “TF+AA” resistance. However, the use of iron-containing TF analogs leads to its doubled cytotoxicity. Conclusion. In leukemia cell line U937 with constitutively active НО-1/Ft the heme-dependent activation of it does not considerably contribute to protection of cells from “TF+AA” toxicity. The system “TF+AA” is HО-1 and Ft expression inducer in U937 myelomonoblasts. Cytotoxic mechanism of “TF+AA” involves intracellular pool of “labile” non-heme iron, the level of which affects the drug sensibility of leukemia cells.
- Open Access
- 15 June 2019
- Published by Publishing House ABV Press in Russian Journal of Biotherapy
- Vol. 18 (2) , 51-59
Teraphtal decreased the sensitivity tumor cells to doxorubicine in vitro but does not affect its antitumor effect in vivo .
Introduction . Anthracycline antibiotic doxorubicin (DOX) is widely used in clinical oncology. It is known that hemin, endogenious compound, has the ability to modulate DOX cytotoxicity. We found that DOX toxicity against mammalian cancer cells can be decreased in vitro in the presence of teraftal (ТF), the component anticancer binaric catalytic system (TF + ascorbic acid).Purpose . To study the influence of TF on anticancer effect of DOX.Materials and methods . The mouse melanoma cell line B16 / F10 and mouse transplanted tumor B16 were used. The TF ability to protect from DOX-induced cell death were measured by MTT-assay, flow сytometry, light microscopy, cytochemical determination of ß-galactosidase expression, radiometric assay and tumor growth inhibition assay in vivo.Results. The sensitivity of mouse melanoma cell line B16 / F10 to DOX decreased in the presence TF (10–20 mkM) in the mean by 4–6 fold. The same mechanism takes part into the decrease of DOX cytotoxicity at the presence of TF / hemin khown which connects with the cell ability to accumulate of drug. TF protect the mouse melanoma cells B16 / F10 from apoptosis, induced by DOX throwing switching on cell premature senescence programme. The antitumor effect of DOX against mouse transplanted melanoma B16 at presence of TF was the same as DOX alone.Conclusions. The TF potency to decrease the sensitivity of cancer cells to DOX in vitro does not correlate with its ability to modulate аnthracycline antibiotics anticancer effect in vivo.
- 15 June 2019
- Published by Publishing House ABV Press in Russian Journal of Biotherapy
- Vol. 18 (2) , 51-59
Open AccessTeraphtal decreased the sensitivity tumor cells to doxorubicine in vitro but does not affect its antitumor effect in vivo .
Introduction . Anthracycline antibiotic doxorubicin (DOX) is widely used in clinical oncology. It is known that hemin, endogenious compound, has the ability to modulate DOX cytotoxicity. We found that DOX toxicity against mammalian cancer cells can be decreased in vitro in the presence of teraftal (ТF), the component anticancer binaric catalytic system (TF + ascorbic acid).Purpose . To study the influence of TF on anticancer effect of DOX.Materials and methods . The mouse melanoma cell line B16 / F10 and mouse transplanted tumor B16 were used. The TF ability to protect from DOX-induced cell death were measured by MTT-assay, flow сytometry, light microscopy, cytochemical determination of ß-galactosidase expression, radiometric assay and tumor growth inhibition assay in vivo.Results. The sensitivity of mouse melanoma cell line B16 / F10 to DOX decreased in the presence TF (10–20 mkM) in the mean by 4–6 fold. The same mechanism takes part into the decrease of DOX cytotoxicity at the presence of TF / hemin khown which connects with the cell ability to accumulate of drug. TF protect the mouse melanoma cells B16 / F10 from apoptosis, induced by DOX throwing switching on cell premature senescence programme. The antitumor effect of DOX against mouse transplanted melanoma B16 at presence of TF was the same as DOX alone.Conclusions. The TF potency to decrease the sensitivity of cancer cells to DOX in vitro does not correlate with its ability to modulate аnthracycline antibiotics anticancer effect in vivo.
- Open Access
- 1 January 2018
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 11 (1) , 10-25
Teraphtal (sodium salt of cobalt 4,5-carboxyphthalocyanine) Decreases Sensitivity of Tumor Cells to Anthracycline Antibiotics and Mitoxantrone in Vitro
Background. Anthracycline antibiotics (AA) are widely used in clinical oncohematology. As is well known АА cytotoxicity diminishes in the presence of hemin (FePPIX), an endogenous metalloporphyrine. Aim. To study effect of teraphtal (TPh) and its structural analog FePPIX on cytotoxicity of “anthraquinone” drugs AA and mitoxantrone (MiTOX) in vitro. Materials & Methods. The study was performed using human leukemia cells of K562 line and HCT 116 adenocarcinoma cell line. TPh ability to prevent AA-induced tumor cell death has been estimated by the following methods: MTT assays, flow cytometry, light microscopy, cytochemical method for determination of b-galactosidase expression using X-Gal substrate, DNA electrophoresis, LDH release, real time RT-PCR, and radiometric method. Results. In the presence of TPh (10 µM) the AA and MiTOX cytotoxicity diminishes approximately 4- and 20-fold respectively. The TPh protective potency is dependent on the AA chemical structure. In the presence of TPh aclarubicin toxicity remains constant. The TPh/FePPIX protection from the AA cytotoxicity can involve the same mechanism reducing the ability of the cells, including the leukemia tumor cells, to accumulate AA in the presence of modulators. TPh/FePPIX protects human tumor cells from AA-induced death, such as apoptosis, necrosis, and accelerated senescence (АS). АS in K562 leukemia cell line induced by AA + TPh/FePPIX results in cell-suspension-derived-small-cell colonies. Вeclin-lysosomal pathway of autophagy is not engaged in reducing of the AA toxicity of K562 cells in the presence of TPh. Conclusion. Reducing of the AA toxicity and revival of cell population growth in the presence of TPh/FePPIX should be taken into consideration when using hematoporphyrins and phthalocyanines having a structure similar to TPh as sensitizers in the chemotherapy protocols.
- 1 January 2018
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 11 (1) , 10-25
Open AccessTeraphtal (sodium salt of cobalt 4,5-carboxyphthalocyanine) Decreases Sensitivity of Tumor Cells to Anthracycline Antibiotics and Mitoxantrone in Vitro
Background. Anthracycline antibiotics (AA) are widely used in clinical oncohematology. As is well known АА cytotoxicity diminishes in the presence of hemin (FePPIX), an endogenous metalloporphyrine. Aim. To study effect of teraphtal (TPh) and its structural analog FePPIX on cytotoxicity of “anthraquinone” drugs AA and mitoxantrone (MiTOX) in vitro. Materials & Methods. The study was performed using human leukemia cells of K562 line and HCT 116 adenocarcinoma cell line. TPh ability to prevent AA-induced tumor cell death has been estimated by the following methods: MTT assays, flow cytometry, light microscopy, cytochemical method for determination of b-galactosidase expression using X-Gal substrate, DNA electrophoresis, LDH release, real time RT-PCR, and radiometric method. Results. In the presence of TPh (10 µM) the AA and MiTOX cytotoxicity diminishes approximately 4- and 20-fold respectively. The TPh protective potency is dependent on the AA chemical structure. In the presence of TPh aclarubicin toxicity remains constant. The TPh/FePPIX protection from the AA cytotoxicity can involve the same mechanism reducing the ability of the cells, including the leukemia tumor cells, to accumulate AA in the presence of modulators. TPh/FePPIX protects human tumor cells from AA-induced death, such as apoptosis, necrosis, and accelerated senescence (АS). АS in K562 leukemia cell line induced by AA + TPh/FePPIX results in cell-suspension-derived-small-cell colonies. Вeclin-lysosomal pathway of autophagy is not engaged in reducing of the AA toxicity of K562 cells in the presence of TPh. Conclusion. Reducing of the AA toxicity and revival of cell population growth in the presence of TPh/FePPIX should be taken into consideration when using hematoporphyrins and phthalocyanines having a structure similar to TPh as sensitizers in the chemotherapy protocols.
- Open Access
- 1 April 2016
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 9 (2)
Soluble Guanylyl Cyclase (sGC) in Mechanisms of Hypotensive and Antiaggregatory Effects Induced by Teraphtal (TP, sodium salt 4,5-cardoxyphtalocyanin-cobalt)
Background & Aims. Many antitumor drugs produces not only the variety of therapeutic effects but also a broad spectrum of side effects, including acute hemodynamic dysfunctions (hypotension/hypertension, coagulation disorders). The aim of the paper is to investigate the role of soluble guanylyl cyclase (sGC) in mechanisms of hypotensive and antiaggregatory effects induced by teraphtal (TP) under experimental conditions in the clinic. Methods. The effect of different products on the basal activity of sGC isolated from platelets of human peripheral blood was assessed by the immunoenzyme method based on production of cyclic guanosine monophosphate (cGMP). The effect of TP on ADP-induced human platelet aggregation was evaluated by the turbidimetric Born method using an aggregometer. Results. In the presence of TP, the basal sGC activity increased by the average of 2.5-fold. The TF-induced dose-response curve of sGC activation displays a bell-shaped behavior with maximal stimulation effect achieved at a concentration of 1 mmol/L. TP does not affect the sGC activation induced by known sGC regulators, such as sodium nitroprusside (SNP) and YC-1. On the other hand, after preliminary incubation of sGC with TP, the ability of YC-1 to potentiate the enzyme stimulation induced by SNP decreased by about 33 %. In vitro tests demonstrated the ability of TP to inhibit the ADP-induced platelet aggregation and established the IC50 value for TP (15 mmol/L). Conclusion. TF is a direct sGC activator and therefore is able to participate in regulation of the NO®sGC®cGMP signaling pathway that controls the basal vascular tone and aggregatory platelet properties. Taking into account the TP characteristics, the paper discusses the involvement of additional mechanisms in the development of hypotension and hemostatic disorders induced by the drug.
- 1 April 2016
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 9 (2)
Open AccessSoluble Guanylyl Cyclase (sGC) in Mechanisms of Hypotensive and Antiaggregatory Effects Induced by Teraphtal (TP, sodium salt 4,5-cardoxyphtalocyanin-cobalt)
Background & Aims. Many antitumor drugs produces not only the variety of therapeutic effects but also a broad spectrum of side effects, including acute hemodynamic dysfunctions (hypotension/hypertension, coagulation disorders). The aim of the paper is to investigate the role of soluble guanylyl cyclase (sGC) in mechanisms of hypotensive and antiaggregatory effects induced by teraphtal (TP) under experimental conditions in the clinic. Methods. The effect of different products on the basal activity of sGC isolated from platelets of human peripheral blood was assessed by the immunoenzyme method based on production of cyclic guanosine monophosphate (cGMP). The effect of TP on ADP-induced human platelet aggregation was evaluated by the turbidimetric Born method using an aggregometer. Results. In the presence of TP, the basal sGC activity increased by the average of 2.5-fold. The TF-induced dose-response curve of sGC activation displays a bell-shaped behavior with maximal stimulation effect achieved at a concentration of 1 mmol/L. TP does not affect the sGC activation induced by known sGC regulators, such as sodium nitroprusside (SNP) and YC-1. On the other hand, after preliminary incubation of sGC with TP, the ability of YC-1 to potentiate the enzyme stimulation induced by SNP decreased by about 33 %. In vitro tests demonstrated the ability of TP to inhibit the ADP-induced platelet aggregation and established the IC50 value for TP (15 mmol/L). Conclusion. TF is a direct sGC activator and therefore is able to participate in regulation of the NO®sGC®cGMP signaling pathway that controls the basal vascular tone and aggregatory platelet properties. Taking into account the TP characteristics, the paper discusses the involvement of additional mechanisms in the development of hypotension and hemostatic disorders induced by the drug.